Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | BCL9 | O00512 | 1/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6516567 | 1.00 | KMT2A (0.41) | KMT2AMEN1CYP1A2NPC1TP53 | |
| SCHEMBL6516559 | 1.00 | KMT2A (0.41) | KMT2AMEN1CYP1A2NPC1TP53 | |
| SCHEMBL12846586 | 0.89 | KMT2A (0.40) | KMT2AMEN1CYP1A2NPC1TP53 | |
| SCHEMBL3310051 | 0.82 | ATM (0.51) | CYP3A4 | |
| SCHEMBL3310047 | 0.82 | ATM (0.51) | CYP3A4 | |
| SCHEMBL3310054 | 0.82 | ATM (0.51) | CYP3A4 | |
| SCHEMBL6521430 | 0.76 | MGLL (0.58) | KMT2AMEN1MAPTALDH1A1MGLL | |
| SCHEMBL2318778 | 0.73 | MEN1 (0.51) | KMT2AMEN1CYP1A2NPC1TP53 | |
| SCHEMBL1219646 | 0.73 | MEN1 (0.53) | KMT2AMEN1NPC1TP53RAB9A | |
| SCHEMBL3404531 | 0.73 | MEN1 (0.53) | KMT2AMEN1NPC1TP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110052674-A1 | ANGIOTENSIN II RECEPTOR BLOCKER DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052674-A1 | ANGIOTENSIN II RECEPTOR BLOCKER DERIVATIVES | AGTR1, AGTR2, AGT | KMT2A 3841/4885MEN1 4297/4885CYP1A2 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.